FAMI
VKTX icon

Fideuram Asset Management (Ireland)’s Viking Therapeutics VKTX Stock Holding History

Fideuram Asset Management (Ireland)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,042
Closed -$65.2K – 756
2026
Q1 		$65.2K Sell
2,042
-132,458
-98% -$4.26M 0.01% 416
2025
Q4 		$5.31M Buy
+134,500
New +$4.77M 0.42% 62

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Fideuram Asset Management (Ireland)'s VKTX Position: Q2 2026 in Review

Fideuram Asset Management (Ireland) sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 2,042 shares — an estimated $65.2K sold.

Fideuram Asset Management (Ireland) first reported a position in VKTX in Q4 2025 and held it in 2 quarters. The position peaked at $5.31M in Q4 2025. 433 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Fideuram Asset Management (Ireland) reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fideuram Asset Management (Ireland) sold 2,042 Viking Therapeutics shares in Q2 2026, an estimated $65.2K.
  • Fideuram Asset Management (Ireland) first reported a position in Viking Therapeutics in Q4 2025 and held it in 2 quarters.
  • Fideuram Asset Management (Ireland)'s Viking Therapeutics position peaked at $5.31M in Q4 2025.
  • 433 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Fideuram Asset Management (Ireland)'s 13F filing for Q2 2026, filed 23 Jul 2026.